SBIR Grant Awarded to Advanced Life Sciences for Proteomics Research

Proteomics investigation in collaboration with Argonne National Laboratory
to focus on treating diseases such as Alzheimer's, type-2 diabetes

Woodridge, IL, June 24, 2003 - The National Institutes of Health has awarded a Small Business Innovation Research Grant (SBIR) to Advanced Life Sciences (ALS) for a promising proteomics-based technology that may eventually lead to treatment of diseases that arise from the faulty aggregation of proteins, such as Alzheimer's, Down's syndrome, adult onset type-2 diabetes and amyloidosis, announced Michael T. Flavin, Ph.D., ALS's chief executive officer. Advanced Life Sciences expects to receive funding from the SBIR Grant beginning in the third quarter 2003.

Advanced Life Sciences will be conducting a portion of their research in collaboration with researchers at Argonne National Laboratory, where ALS in-licensed the basic technology. "This grant will help ALS to further elucidate the science behind faulty protein-protein aggregation. We are optimistic it will lead to development of a platform technology that will spawn multiple effective therapeutic agents to treat a variety of protein aggregation diseases," said Dr. Flavin.

The focus of the grant, entitled "Design & Synthesis of Novel Agents to Treat Amyloidosis" will be the development of novel small molecules, which are intended to interfere in vivo with specific protein-protein interactions and to identify their binding sites. "The formation of protein fibrils, or bunches, is a component of many untreatable protein aggregation diseases," said Dr. Ze-Qi Xu, ALS's chief scientific officer. "One strategy for minimizing protein aggregation is to stabilize the proteins, or disassociate the protein aggregates, with small molecules. We intend to use high-throughput screening to identify naturally occurring and synthetic small molecules that can be effective against fibril formation."

Advanced Life Sciences is a privately held biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation using its platform in natural products and chemical proteomics coupled with expertise in drug development. (